Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurite Density Explains Cortical T1-/T2-Weighted Ratio in Multiple Sclerosis
Multiple Sclerosis
S2 - Advances in MS Imaging (2:00 PM-2:08 PM)
001
Cortical damage is clinically relevant in MS, however reliable MRI markers for its monitoring are still an unmet need. T1w/T2w-ratio is a clinically feasible MRI measure to assess cortical abnormalities in PwMS, but its histopathological substrate has yet to be definitively elucidated.

To define the histopathological substrate of the ratio of T1-weighted (T1w) and T2-weighted (T2w) sequences (i.e., T1w/T2w-ratio) in normal-appearing and demyelinated cortices of patients with multiple sclerosis (PwMS) by performing a combined post-mortem MRI/histopathology study.

Fifteen PwMS and ten age- and sex-matched non-neurological controls (nNC) underwent post-mortem in situ 3T MRI with 3D T1w and T2w sequences, followed by brain dissection. One hundred and five paraffin-embedded tissue blocks (n=49 from PwMS, n=56 from nNC) were collected. Tissue regions were matched to T1w/T2w-ratio maps to obtain regional cortical T1w/T2w-ratio. Using immunohistochemistry and silver staining, cortical density of myelin and neurites were evaluated. Correlates of T1w/T2w-ratio alterations with histological markers were assessed through linear mixed-effects models.

Twenty-six cortical lesions (85% subpial) were found in 24/49 (51%) cortical regions from PwMS. Compared to nNC’s cortex, PwMS’ normal-appearing and demyelinated cortices had a significantly lower T1w/T2w-ratio (p=0.045 and 0.001). In PwMS, T1w/T2w-ratio was significantly lower in demyelinated vs normal-appearing cortex (p=0.007). In PwMS, neurite density was significantly lower in both normal-appearing and demyelinated cortices vs nNC (p=0.041 and 0.001), and in demyelinated vs normal-appearing cortex (p=0.048). Demyelinated cortex showed also significant lower myelin density vs normal-appearing cortex in both nNC and PwMS (p<0.001). Cortical T1w/T2w-ratio was positively associated with neurite density (β=3.464×10-2, p=0.004), whereas only a trend for myelin density was found (p=0.082).

T1w/T2w-ratio is sensitive to MS cortical damage. Although both demyelination and neurite loss occur in MS cortex, T1w/T2w-ratio seems more strongly associated to cortical neurite than myelin density. T1w/T2w-ratio could be useful to investigate cortical damage in MS.

Authors/Disclosures
Paolo Preziosa (Ospedale San Raffaele)
PRESENTER
Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
No disclosure on file
No disclosure on file
No disclosure on file
Alessandro Meani No disclosure on file
No disclosure on file
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
No disclosure on file
No disclosure on file